<DOC>
	<DOCNO>NCT02380521</DOCNO>
	<brief_summary>The glucagon-like peptide 1 ( GLP-1 ) agonist exenatide represent effective therapy patient type 2 diabetes mellitus ( T2DM ) , also seem important non-glycemic effect . Yet , non-glycemic effect still largely unknown . The effect exenatide weekly investigate control , blind open-label clinical study subject T2DM control diet exercise alone combination oral antidiabetic agent , also multi-dose controlled study study result significant reduction glycemic parameter ( mean glycated hemoglobin ( HbA1c ) , fast serum/plasma glucose well postprandial plasma glucose level ) , also body weight , 24 30 week . Meaningful reduction observe early week 4 treatment , maintain 6 year treatment . The study investigate cardiovascular effect exenatide weekly currently undergo . The result available numerous ( DURATION-2 , DURATION-3 , DURATION-4 study ) lead definitive conclusion . In study investigator evaluate effect exenatide once-weekly multiple cardiovascular risk marker . These marker relate subclinical atherosclerosis , endothelial dysfunction , oxidative stress atherogenic lipoprotein . The investigator perform open label , single-arm , prospective , intervention study use exenatide weekly period 8 month 60 patient T2DM .</brief_summary>
	<brief_title>Exenatide Once Weekly , Cardiovascular Risk Type-2 Diabetes</brief_title>
	<detailed_description>The research hypothesis ass whether exenatide weekly reduce subclinical atherosclerosis ( measure carotid-intima medium thickness [ cIMT ] ) patient T2DM . The primary objective ass whether exenatide weekly reduce subclinical atherosclerosis ( measure cIMT ) patient T2DM . Primary endpoint : Reduction cIMT . The secondary objective ass whether exenatide weekly reduce atherogenic lipoprotein , oxidative stress endothelial dysfunction patient T2DM . Secondary endpoint : Reduction atherogenic lipoprotein , oxidative stress improvement endothelial dysfunction . The purpose present 8 month study elucidate largely unknown non-glycemic effect exenatide add-on metformin , include effect cIMT , oxidative stress parameter atherogenic lipoprotein , addition benefit glycemic control , weight loss efficacy parameter , well safety profile exenatide . The data clinical biochemical analysis , include collection efficacy variable , ECG , pulse physical examination , collect baseline 8 month therapy ( 6 month treatment , routine laboratory analysis , include HbA1c , perform ) . Clinical diagnostic tool include measurement : 1. cIMT , assess B-mode real-time ultrasound use single sonographer ( Medison SonoAce Pico , probe 7.5-10.0 MHz ) standardize manner fixed angle insonation ; 2 . Endothelial dysfunction , assess flow mediate dilation brachial artery . Biochemical analysis include analysis : 1 . Routine testing : blood testing , liver kidney profile , plasma lipid , glucose metabolism parameter ; 2 . Oxidative stress parameter ( plasma glutathione , serum lipid hydroperoxides , reactive oxygen specie ) ; 3 . Atherogenic lipoprotein , e.g . analysis 11 distinct lipoprotein include very-low-density lipoprotein ( VLDL ) , 3 intermediate density lipoprotein ( IDL ) subclasses 7 low density lipoprotein ( LDL ) subclasses .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedure ; 2 . Men woman T2DM age &gt; 18 year ; 3 . BMI &gt; 25 kg/m2 ; 4 . HbA1c 7.58.5 % ; 5 . Receiving metformin therapy ( dose range 1500 3000 mg daily ) least 8 week . 1 . Pregnancy willingness become pregnant ; 2 . Moderate severe liver dysfunction ; 3 . Moderate severe renal failure ; 4 . Previous major cardiovascular event ; 5 . Severe infection discretion investigator ( human immunodeficiency virus [ HIV ] , hepatitis B virus [ HBV ] hepatitis C virus [ HCV ] ) ; 6 . Any malignancy ; 7 . Plasma triglycerides &gt; 400 mg/dL , plasma LDLcholesterol &gt; 250 mg/dL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Exenatide weekly</keyword>
	<keyword>T2DM</keyword>
	<keyword>IMT</keyword>
	<keyword>Atherogenic lipoprotein</keyword>
</DOC>